SP-3164, an investigational small molecule protein degrader, showed potential for improved anti-multiple myeloma activity over similar approved compounds. That’s according to preclinical data from…
News
Caribou Biosciences will soon start testing its new CAR T-cell therapy candidate, CB-011, in people with relapsed or refractory multiple myeloma. A Phase…
GC012F, Gracell Biotechnologies’ investigational dual FastCAR T-cell therapy, was safe and highly effective at eradicating cancer cells in people with high-risk, newly diagnosed…
The U.S. Food and Drug Administration (FDA) will review BioLineRx’s application to approve Aphexda, formerly known as motixafortide, as an add-on stem cell…
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what…
Janssen’s Tecvayli (teclistamab) has been approved for certain adults with relapsed or refractory multiple myeloma in the U.S., but access is limited due…
The first patient has been dosed in Ichnos Sciences’ Phase 1/2 clinical trial investigating ISB 1442, an experimental bi-specific antibody treatment for people with…
A new investigational CAR T-cell therapy, called MCARH109, demonstrated an ability to shrink or eliminate the amount of cancer in patients with relapsed or refractory…
The International Myeloma Foundation’s (IMF) M-Power project, which seeks to improve disease outcomes for African Americans with multiple myeloma, has formed a partnership with…
An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient…
